CME/CE Information

Activity Title Updates in MS
Topic Multiple Sclerosis
Accreditation Type AMA PRA Category 1 Credit
Release Date July 31, 2014
Expiration Date July 30, 2015
Estimated Time to Complete Activity 60 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Review latest research and clinical information available on the accurate diagnosis of MS
  • Review latest research and clinical information available on the appropriate treatment of MS


FACULTY

Barbara Giesser, MD
Vice Chair, Education and Clinical Affairs, Neurology
Professor, Neurology
UCLA Health
Los Angeles, California

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Medical Center
Maywood, Illinois

Bryan Walker, PA-C
Assistant Professor of Physician Assistant Studies
George Washington School of Medicine & Health Sciences
Washington, District of Columbia


METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Your CME/CE certificate will be available for download


TECHNICAL REQUIREMENTS

This site is best viewed using Internet Explorer 8.0 or higher, Google Chrome 29.0 or higher, Firefox 4.0 or higher. For interactive content, a broadband connection is required. For all CME/CE activities featuring audio you must have a sound card and speakers.

Our interactive activities may require the Adobe Flash Player (available from the Adobe Web site) and Adobe Shockwave Player (available from the Adobe Web site). Both browser plug-ins are free.

Our activities may require JavaScript to be enabled on your computer.


SPONSOR

This activity is sponsored by The France Foundation.


TARGET AUDIENCE

This activity is intended for neurologists, neurology nurses and nurse practitioners, neurology physician assistants, case workers and any other healthcare providers involved in the care of patients with MS.


STATEMENT OF NEED

Multiple sclerosis (MS) affects more than 350,000 people in the United States and 2.5 million worldwide. In the United States, prevalence estimates are approximately 90 per 100,000 population and MS-related health care costs are estimated to be more than $10 billion annually in the United States. Advances continue in the diagnosis and management of the disease.

Constant developments in treatment options available for MS patients are occurring. Interferon beta (IFN-β), the first therapy in randomized trials to reduce the number of relapses that people with MS experience, has revolutionized the management of MS, and introduced the concept of disease-modifying treatment (DMT). The year 2010 marked the beginning of the era of oral medications for the treatment of MS, with the approval of dalfampridine to improve walking and fingolimod as the first oral disease-modifying agent. Therapeutics in late-stage development for MS include non-selective immunosupressants, targeted immune-modulators, and monoclonal antibodies. Oral agents including cladribine and laquinimod, as well as monoclonal antibodies alemtuzumab, daclizumab, ofatumumab, ocrelizumab and rituximab are also being studied. The emergence of oral disease-modifying therapies, such as the recently approved oral agents teriflunomide and dimethyl fumarate, will have a significant impact on the evolving scenario of immunomodulatory treatments in MS where current therapies are all injectable (with the exception of fingolimod).


ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.


CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
This program has been reviewed and is approved for a maximum of 1.00 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of 09/01/2014. Participants may submit the self-assessment at any time during that period.

This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Nurses
This continuing nursing education activity was approved by the North Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This activity has been awarded 1 contact hour.


DISCLOSURES

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.


Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.


Faculty Disclosure

The following faculty has indicated she has relationships with industry to disclose relative to the content of this CME/CE activity:

  • Barbara Giesser, MD, has disclosed her spouse is a stock shareholder of Biogen Idec and Pfizer.
  • Amy Perrin Ross, APN, MSN, CNRN, MSCN, has served as a consultant for Acorda, Bayer Healthcare, EMD Sorono, Genzyme, Novartis, Questcor, and Teva. She has received honoraria from Acorda, Bayer Healthcare, Biogen Idec, EMD Serono, Genzyme, Novartis, Pfizer, Questcor, and Teva.
  • Bryan Walker, PA-C, is a stock shareholder of Biogen Idec.

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from EMD Serono and Teva CNS.


DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation assumes no liability for the information herein.


COPYRIGHT INFORMATION

Copyright © 2014 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.


PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.


CONTACT INFORMATION

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.